




ELSEVIER

Contents lists available at ScienceDirect

International Journal of Antimicrobial Agents

journal homepage: www.elsevier.com/locate/ijantimicag

Corrigendum

Corrigendum to "Multicentre study of risk factors for mortality in patients with *Acinetobacter* bacteraemia receiving colistin treatment" [International Journal of Antimicrobial Agents 55 (2020) 105956]

Yi-Tzu Lee^{a,b}, Jun-Ren Sun^c, Yung-Chih Wang^d, Chun-Hsiang Chiu^d, Shu-Chen Kuo^e, Te-Li Chen^{f,g}, the ACTION Study Group, Ya-Sung Yang^{d,*}

^a Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

^b Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

^c Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan

^d Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

^e National Institute of Infectious Diseases and Vaccinology, National Health Research Institute, Maoli County, Taiwan

^f Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan

^g Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

The authors regret that Figure 2 was incorrect. Please find here the correct Figure 2 and its caption.

DOI of original article: [10.1016/j.ijantimicag.2020.105956](https://doi.org/10.1016/j.ijantimicag.2020.105956)

* Corresponding author at: Division of Infectious Diseases and Tropical Medicine, Tri-Service General Hospital, No. 325, Section 2, Cheng-Kung Road, Taipei City 11490, Taiwan. Tel.: +886 2 8792 7257; fax: +886 2 8792 7258.

E-mail address: ysyoung4097@gmail.com (Y.-S. Yang).

<https://doi.org/10.1016/j.ijantimicag.2021.106333>

0924-8579/© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Please cite this article as: Y.-T. Lee, J.-R. Sun, Y.-C. Wang et al., Corrigendum to "Multicentre study of risk factors for mortality in patients with *Acinetobacter* bacteraemia receiving colistin treatment" [International Journal of Antimicrobial Agents 55 (2020) 105956], International Journal of Antimicrobial Agents, <https://doi.org/10.1016/j.ijantimicag.2021.106333>




Fig. 2. Fig.2. Kaplan-Meier 14-day survival curves of (A) patients with *Acinetobacter* bacteraemia caused by colistin-resistant ($MIC \geq 4$ mg/L) and colistin-susceptible ($MIC \leq 2$ mg/L) isolates, (B) patients with *Acinetobacter* bacteraemia receiving colistin monotherapy or colistin in combination with a carbapenem or tigecycline therapies and (C) patients with bacteraemia caused by *Acinetobacter baumannii* and non-*baumannii* *Acinetobacter* isolates. MIC, minimum inhibitory concentration.

The authors would like to apologise for any inconvenience caused.